<DOC>
	<DOCNO>NCT00238264</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study well radiation therapy work treat young patient glioma .</brief_summary>
	<brief_title>Radiation Therapy Treating Young Patients With Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine marginal-failure rate young patient low-grade glioma treat reduced-field conformal radiotherapy . Secondary - Determine progression-free survival , event-free survival , overall survival rate young patient treated regimen . - Determine quality life patient treat regimen . - Correlate MIB-1 label index progression-free survival overall survival patient . OUTLINE : This multicenter study . Patients undergo reduced-field conformal radiotherapy 5 day week 6 week absence disease progression unacceptable toxicity . Quality life assess baseline 6 week completion study treatment 2 5 year ( close 10/27/2010 ) . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* lowgrade glioma , include follow : Juvenile pilocytic astrocytoma ( JPA ) pleomorphic JPA Diffuse astrocytoma , include follow subtypes : Fibrillary astrocytoma Gemistocytic astrocytoma Subependymal giant cell astrocytoma Pleomorphic xanthoastrocytoma Lowgrade oligoastrocytoma Lowgrade oligodendroglioma Lowgrade glioma otherwise specified NOTE : *Patients chiasmatic lesion contiguous extension tumor region visual pathway CT scan MRI eligible without histopathologic confirmation ; repeat biopsy require patient recurrent tumor enhance whose initial tumor Measurable disease radiography Meets follow criterion : Progressive nonresectable disease Any location brain Patients le gross total resection eligible provide symptomatic tumor OR risk neurologic impairment progression high enough warrant immediate treatment Has undergone biopsy Must receive ≥ 1 course prior chemotherapy ( patient &lt; 10 year age ) Prior chemotherapy optional ( patient ≥ 10 year age ) No type1 neurofibromatosis No evidence leptomeningeal dissemination PATIENT CHARACTERISTICS : Age 3 20 Performance status ECOG 02 OR Karnofsky 50100 % ( patient &gt; 16 year age ) OR Lansky 50100 % ( patient ≤ 16 year age ) Life expectancy At least 1 year Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) Hepatic Not specify Renal Not specify Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception Not status epilepticus , coma , require assist ventilation prior study entry Patients seizure disorder eligible provide anticonvulsant AND disease well control PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Recovered prior chemotherapy No concurrent chemotherapy Endocrine therapy Concurrent dexamethasone allow provided patient stable dose ≥ 2 week prior study entry Concurrent dexamethasone allow symptom increase intracranial pressure Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Other No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
</DOC>